Alicia N M Kraay1, Edward L Ionides2, Gwenyth O Lee1, William F Cevallos Trujillo3, Joseph N S Eisenberg1. 1. Department of Epidemiology, University of Michigan-Ann Arbor, Ann Arbor, MI, USA. 2. Department of Statistics, University of Michigan-Ann Arbor, Ann Arbor, MI, USA. 3. Centro de Biomedicina, Facultad de Ciencias Médicas, Universidad Central del Ecuador, Quito, Ecuador.
Abstract
BACKGROUND: Although live attenuated monovalent human rotavirus vaccine (Rotarix) efficacy has been characterized through randomized studies, its effectiveness, especially in non-clinical settings, is less clear. In this study, we estimate the impact of childhood Rotarix® vaccination on community rotavirus prevalence. METHODS: We analyse 10 years of serial population-based diarrhoea case-control study, which also included testing for rotavirus infection (n = 3430), and 29 months of all-cause diarrhoea active surveillance from a child cohort (n = 376) from rural Ecuador during a period in which Rotarix vaccination was introduced. We use weighted logistic regression from the case-control data to assess changes in community rotavirus prevalence (both symptomatic and asymptomatic) and all-cause diarrhoea after the vaccine was introduced. We also assess changes in all-cause diarrhoea rates in the child cohort (born 2008-13) using Cox regression, comparing time to first all-cause diarrhoea case by vaccine status. RESULTS: Overall, vaccine introduction among age-eligible children was associated with a 82.9% reduction [95% confidence interval (CI): 49.4%, 94.2%] in prevalence of rotavirus in participants without diarrhoea symptoms and a 46.0% reduction (95% CI: 6.2%, 68.9%) in prevalence of rotavirus infection among participants experiencing diarrhoea. Whereas all age groups benefited, this reduction was strongest among the youngest age groups. For young children, prevalence of symptomatic diarrhoea also decreased in the post-vaccine period in both the case-control study (reduction in prevalence for children <1 year of age = 69.3%, 95% CI: 8.7%, 89.7%) and the cohort study (reduction in hazard for receipt of two Rotarix doses among children aged 0.5-2 years = 57.1%, 95% CI: 16.6, 77.9%). CONCLUSIONS: Rotarix vaccination may suppress transmission, including asymptomatic transmission, in low- and middle-income settings. It was highly effective among children in a rural community setting and provides population-level benefits through indirect protection among adults.
BACKGROUND: Although live attenuated monovalent human rotavirus vaccine (Rotarix) efficacy has been characterized through randomized studies, its effectiveness, especially in non-clinical settings, is less clear. In this study, we estimate the impact of childhood Rotarix® vaccination on community rotavirus prevalence. METHODS: We analyse 10 years of serial population-based diarrhoea case-control study, which also included testing for rotavirus infection (n = 3430), and 29 months of all-cause diarrhoea active surveillance from a child cohort (n = 376) from rural Ecuador during a period in which Rotarix vaccination was introduced. We use weighted logistic regression from the case-control data to assess changes in community rotavirus prevalence (both symptomatic and asymptomatic) and all-cause diarrhoea after the vaccine was introduced. We also assess changes in all-cause diarrhoea rates in the child cohort (born 2008-13) using Cox regression, comparing time to first all-cause diarrhoea case by vaccine status. RESULTS: Overall, vaccine introduction among age-eligible children was associated with a 82.9% reduction [95% confidence interval (CI): 49.4%, 94.2%] in prevalence of rotavirus in participants without diarrhoea symptoms and a 46.0% reduction (95% CI: 6.2%, 68.9%) in prevalence of rotavirus infection among participants experiencing diarrhoea. Whereas all age groups benefited, this reduction was strongest among the youngest age groups. For young children, prevalence of symptomatic diarrhoea also decreased in the post-vaccine period in both the case-control study (reduction in prevalence for children <1 year of age = 69.3%, 95% CI: 8.7%, 89.7%) and the cohort study (reduction in hazard for receipt of two Rotarix doses among children aged 0.5-2 years = 57.1%, 95% CI: 16.6, 77.9%). CONCLUSIONS: Rotarix vaccination may suppress transmission, including asymptomatic transmission, in low- and middle-income settings. It was highly effective among children in a rural community setting and provides population-level benefits through indirect protection among adults.
Authors: Guillermo M Ruiz-Palacios; Irene Pérez-Schael; F Raúl Velázquez; Hector Abate; Thomas Breuer; SueAnn Costa Clemens; Brigitte Cheuvart; Felix Espinoza; Paul Gillard; Bruce L Innis; Yolanda Cervantes; Alexandre C Linhares; Pío López; Mercedes Macías-Parra; Eduardo Ortega-Barría; Vesta Richardson; Doris Maribel Rivera-Medina; Luis Rivera; Belén Salinas; Noris Pavía-Ruz; Jorge Salmerón; Ricardo Rüttimann; Juan Carlos Tinoco; Pilar Rubio; Ernesto Nuñez; M Lourdes Guerrero; Juan Pablo Yarzábal; Silvia Damaso; Nadia Tornieporth; Xavier Sáez-Llorens; Rodrigo F Vergara; Timo Vesikari; Alain Bouckenooghe; Ralf Clemens; Béatrice De Vos; Miguel O'Ryan Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245
Authors: Joseph N S Eisenberg; William Cevallos; Karina Ponce; Karen Levy; Sarah J Bates; James C Scott; Alan Hubbard; Nadia Vieira; Pablo Endara; Mauricio Espinel; Gabriel Trueba; Lee W Riley; James Trostle Journal: Proc Natl Acad Sci U S A Date: 2006-12-07 Impact factor: 11.205
Authors: Catherine Yen; Julio A Armero Guardado; Patricia Alberto; David S Rodriguez Araujo; Carlos Mena; Elizabeth Cuellar; Jenny Brenda Nolasco; Lucia Helena De Oliveira; Desiree Pastor; Jacqueline E Tate; Umesh D Parashar; Manish M Patel Journal: Pediatr Infect Dis J Date: 2011-01 Impact factor: 2.129
Authors: K B Phua; F S Lim; Y L Lau; E A S Nelson; L M Huang; S H Quak; B W Lee; Y L Teoh; H Tang; I Boudville; L C Oostvogels; P V Suryakiran; I V Smolenov; H H Han; H L Bock Journal: Vaccine Date: 2009-08-11 Impact factor: 3.641
Authors: Julia M Baker; Jacqueline E Tate; Claudia A Steiner; Michael J Haber; Umesh D Parashar; Benjamin A Lopman Journal: Clin Infect Dis Date: 2019-03-05 Impact factor: 9.079
Authors: Karen L Kotloff; James P Nataro; William C Blackwelder; Dilruba Nasrin; Tamer H Farag; Sandra Panchalingam; Yukun Wu; Samba O Sow; Dipika Sur; Robert F Breiman; Abu Sg Faruque; Anita Km Zaidi; Debasish Saha; Pedro L Alonso; Boubou Tamboura; Doh Sanogo; Uma Onwuchekwa; Byomkesh Manna; Thandavarayan Ramamurthy; Suman Kanungo; John B Ochieng; Richard Omore; Joseph O Oundo; Anowar Hossain; Sumon K Das; Shahnawaz Ahmed; Shahida Qureshi; Farheen Quadri; Richard A Adegbola; Martin Antonio; M Jahangir Hossain; Adebayo Akinsola; Inacio Mandomando; Tacilta Nhampossa; Sozinho Acácio; Kousick Biswas; Ciara E O'Reilly; Eric D Mintz; Lynette Y Berkeley; Khitam Muhsen; Halvor Sommerfelt; Roy M Robins-Browne; Myron M Levine Journal: Lancet Date: 2013-05-14 Impact factor: 79.321
Authors: Albert Jan van Hoek; Mwanajuma Ngama; Amina Ismail; Jane Chuma; Samuel Cheburet; David Mutonga; Tatu Kamau; D James Nokes Journal: PLoS One Date: 2012-10-24 Impact factor: 3.240
Authors: James A Platts-Mills; Jie Liu; Elizabeth T Rogawski; Furqan Kabir; Paphavee Lertsethtakarn; Mery Siguas; Shaila S Khan; Ira Praharaj; Arinao Murei; Rosemary Nshama; Buliga Mujaga; Alexandre Havt; Irene A Maciel; Timothy L McMurry; Darwin J Operario; Mami Taniuchi; Jean Gratz; Suzanne E Stroup; James H Roberts; Adil Kalam; Fatima Aziz; Shahida Qureshi; M Ohedul Islam; Pimmada Sakpaisal; Sasikorn Silapong; Pablo P Yori; Revathi Rajendiran; Blossom Benny; Monica McGrath; Benjamin J J McCormick; Jessica C Seidman; Dennis Lang; Michael Gottlieb; Richard L Guerrant; Aldo A M Lima; Jose Paulo Leite; Amidou Samie; Pascal O Bessong; Nicola Page; Ladaporn Bodhidatta; Carl Mason; Sanjaya Shrestha; Ireen Kiwelu; Estomih R Mduma; Najeeha T Iqbal; Zulfiqar A Bhutta; Tahmeed Ahmed; Rashidul Haque; Gagandeep Kang; Margaret N Kosek; Eric R Houpt Journal: Lancet Glob Health Date: 2018-10-01 Impact factor: 26.763